Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216865 | 0.79 | ACHE (0.43) | SLC6A3MAPK1MEN1KMT2ANPSR1 | |
| SCHEMBL7216927 | 0.78 | KDM4E (0.49) | SMN1; SMN2KDM4ESLC6A3MAPK1ALDH1A1 | |
| SCHEMBL7215357 | 0.77 | PRCP (0.40) | SLC6A3MEN1KMT2ANPSR1PRCP | |
| SCHEMBL7220444 | 0.76 | PRCP (0.41) | SLC6A3NPSR1PRCP | |
| SCHEMBL7214547 | 0.71 | MAOB (0.39) | SLC6A3MEN1KMT2ANPSR1PRCP | |
| SCHEMBL7220570 | 0.69 | KCNH2 (0.37) | MAPK1ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL7216749 | 0.69 | LOXL2 (0.38) | SLC6A3 | |
| SCHEMBL7216729 | 0.69 | ACHE (0.48) | SLC6A3NPSR1PRCP | |
| SCHEMBL7220263 | 0.68 | QPCT (0.37) | — | |
| SCHEMBL7220239 | 0.68 | ACHE (0.52) | KDM4ESLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |